Stock comparison

ABBVvsREGN

AbbVie IncvsRegeneron Pharmaceuticals Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

ABBV

AbbVie Inc

$200.95

-12.05%

Biotechnology$362.8BNYSE
REGN

Regeneron Pharmaceuticals Inc

$766.02

+3.34%

Biotechnology$79.2BNASDAQ

60-day price, rebased to 100

ABBV -8.25% · REGN +1.98%

Round-by-round

ABBV 3·REGN 3
EdgeREGN

Valuation upside

-48.60% vs -22.60% to DCF fair value

EdgeREGN

Balance-sheet strength

Altman Z 2.25 vs 7.40

EdgeABBV

Fundamental quality

Piotroski 7.00 vs 5.00 (of 9)

EdgeABBV

Growth + margins

Rule-of-40 37.70 vs 27.20

EdgeREGN

60-day momentum

-8.25% vs +1.98% price return

EdgeABBV

Market-cap liquidity

$362.8B vs $79.2B

Verdict

Across6categories,the two names are evenly matched —3wins each. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onABBVorREGN

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.

For informational and educational purposes only. Not financial advice. Learn more